Clinical Trial Update: Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of HuCNS-SC for Neuronal Ceroid Lipofuscinosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuronal Ceroid Lipofuscinosis

Drugs mentioned

• HuCNS-SC

Snippet

Sponsor: StemCells, Inc. | Conditions: Neuronal Ceroid Lipofuscinosis | Phase 1 | Status: WITHDRAWN